The agreement is for 30 million doses, which can be expanded to 400 million doses in the UK.
Wockhardt share price jumped 8 percent in the morning trade on August 4, surging over 24 in last three days after the company announced a COVID-19 vaccine partnership with the UK government.
Wockhardt said it had entered into an agreement with the UK government to fill-finish COVID-19 vaccines. The manufacturing will be undertaken at CP Pharmaceuticals, a subsidiary of Wockhardt based in Wrexham, North Wales.
"As per the terms of the agreement, the company has reserved manufacturing capacity to allow for the supply of multiple vaccines to the UK government in its fight against COVID19, including AZD1222, the vaccine co-invented by the University of Oxford and its spinout company, Vaccitech, and licensed by AstraZeneca," the company said.
The agreement is for 30 million doses, which can be expanded to 400 million doses in the UK.
Habil Khorakiwala, Founder Chairman of Wockhardt said the company has total capacity in the UK and India to fill and finish one billion doses of vaccine.
The stock price was trading at Rs 326.20, up Rs 22.80, or 7.51 percent at 09:31 hours. It has touched an intraday high of Rs 333.70 and an intraday low of Rs 308. The scrip was trading with volumes of 281,997 shares, compared to its five day average of 140,759 shares, an increase of 100.34 percent.
It was also one of the most active stocks on NSE in terms of value with 31,07,966 shares being traded.